Anton pozniak biography
Home / Celebrity Biographies / Anton pozniak biography
Abstract LB-18
3. As with all antiretroviral agents, the development of resistance is a potential issue and mutations in the gp41 that map to the binding region for T-20 have been observed.
He is on the board of the Charity CUAMM UK. He has published widely on clinical aspects of HIV treatment and care and HIV tuberculosis.
Professor Anton Pozniak is Consultant Physician in HIV Medicine and Lead TB
Physician, Chelsea and Westminster Hospital London, UK and Professor in the
Department of Clinical Research, London School of Hygiene and Tropical Medicine, UK.
He became a Fellow of the Royal College of Physicians in 1996, and life member of the
British HIV Association in 2014.
He is President of the European AIDS Trial Network NEAT-ID, Principal Investigator for a Test and Treat project in Tanzania, and a Life member of the British HIV Association (BHIVA) and is on the BHIVA anti-viral HIV guidelines and chairs the TB/HIV guidelines committee. Given the potential impact of this on long-term patient acceptance, a T20-205 Activities of Daily Living (ADL) survey was conducted, which required patients to complete written questionnaires at baseline and at week 48 of the 205 study.
Kilby JM, Hopkins S, Venetta TM et al. Cohen C, Lalezari J, Eron J et al. Dr Pozniak has published widely on HIV and AIDS. In addition, he is on the board of the Charity CUAMM UK. He was President of the International AIDS Society from 2018-2020, and he has published widely on clinical aspects of HIV treatment and HIV/tuberculosis.
Trials of T-20 started with a small Phase I, proof-of-concept trial, moving on to dosage and formulation studies.
These results are particularly significant when one considers that these patients were heavily antiretroviral-experienced and did not initiate T-20 therapy with a new background regimen. It is hoped that this more convenient regimen will benefit the patient since the number of daily injections has been reduced from four to two.
As a final point, it is pertinent to balance the positive results seen to date with T-20 against the challenges that face the future development of this drug.
He has been an advisor on HIV and AIDS to the UK
Government Health Select Committee and part of the expert advisory group on AIDS for the UK
Department of Health.
President of the International AIDS Society and a Governing board and ARV guidelines committee member of the European AIDS Clinical Society.
He returned to the UK to join the Academic Department of Genito-urinary Medicine at the Middlesex, then moving as Senior Lecturer and Honorary Consultant at King's Healthcare NHS Trust in 1992. It acts by adhering to the N terminal of gp41, preventing the C terminal folding back in an
anti-parallel fashion, thereby preventing subsequent viral-cell fusion (see figure 1).
Figure 1
T-20 has demonstrated activity in T-cell lines at nanomolar concentrations.
There is no doubt that T-20 represents a potentially important new addition to HIV therapeutic management tools and further data are eagerly awaited.
References
1. He started caring for patients with HIV in 1983 in London UK. In 1989 he went to Zimbabwe as a Consultant Physician where he researched for his doctorate in TB/HIV and moved back to the UK in 1991.
Nature Medicine 1998; 4:1302-1307
2. At baseline, mean HIV RNA levels were 5.0 log 10 copies/ml and median CD4 count was 90 cells/mm 3 . He is a board member of the charity CUAMM UK.
He has published over 400 peer reviewed papers mainly on clinical aspects of HIV treatment and care and HIV associated tuberculosis.
Prof Pozniak studied medicine at the University of Bristol UK and qualified in 1979.